In recent years, AI-driven biotechnology has experienced an unprecedented boom. Companies that once required massive human teams for drug discovery, clinical trials, and commercial agreements are now exploring architectures where AI agents take on specialized roles. However, a recent study (arXiv:2607.18696v1) raises an uncomfortable question: does it make sense to copy human org charts into these AI-native organizations? The answer, according to the authors, is a resounding no. Instead, they propose a 'Company World Model' that treats assets as persistent states, with transition models, explicit value functions, and continuous planning. This approach challenges the traditional notion of departments and suggests that the core operating primitive should be a shared state mapping assets to value, not a static org chart. For a company like Q2BSTUDIO, a specialist in custom software development, this reflection is especially relevant. When building software solutions for biotechs, we have observed that departmental rigidity often hinders innovation. A system that integrates research, regulatory, financial, and commercial data into a single predictive model can outperform any traditional organizational structure.
The study presented a benchmark of 45 retrospective public decision cases, using strict time cutoffs and hidden outcomes. It compared four architectures: one mimicking the human org chart (human-org-mimic), an enhanced version (human-org-mimic-plus), an asset-centric design, and a value-conversion architecture—the latter being a prompt-level approximation of the Company World Model. The value-conversion architecture includes a Live Asset Value Record updated by Deal, Approval, Revenue, and Investment Arbiter loops. Under a success function combining external BD deals, regulatory approvals, and revenue discipline, this architecture achieved the highest automatic value-conversion score and was preferred by value-specific blinded judges. However, stress tests narrowed the claim: a stronger human baseline remained competitive, and a neutral judge did not show robust dominance. This suggests departments are not useless, but secondary to a shared asset-to-value model.
For AI-native biotechs, the lesson is clear: instead of replicating a legacy structure, they should design systems that dynamically capture how each asset (a compound, a patent, a deal) transforms into real value. This means integrating data from multiple sources—scientific, regulatory, business intelligence—into a single model. This is where Q2BSTUDIO's expertise in artificial intelligence and AI agents makes a difference. We have developed platforms that unify R&D processes, clinical trial management, and market tracking under a single ecosystem of intelligent agents. These agents are not trapped in departments; they act according to a global asset state, updating value predictions in real time. For instance, a discovery agent can alert the development team about a potential molecular synergy, while a regulatory agent anticipates approval requirements based on historical data—all without rigid departmental boundaries.
Does this mean departments will disappear entirely? Probably not. The study suggests departments can remain useful as governance views, but not as the core operating primitive. A company may keep review committees or business units, but the decision-making core should be a shared, predictive model. This mirrors how software companies have evolved from siloed teams to integrated DevOps platforms. In biotech, the analogy is even more powerful: trial, regulatory, and commercial data flow constantly; a system that processes them together offers immense competitive advantage.
For Q2BSTUDIO, this paradigm is perfectly applicable beyond biotechnology. Our cloud services on AWS and Azure enable scalable infrastructures to support these company world models. Cybersecurity also plays a critical role, as the centralized asset model can become a target if not properly protected. We implement security layers in every agent interaction. Similarly, business intelligence with Power BI allows visualizing the asset value state for top management. And all of this connects via process automation that eliminates departmental bottlenecks.
In conclusion, the question 'Do AI-native biotechs need departments?' has no binary answer. Departments may exist as governance layers, but the main engine should be a shared, predictive asset-to-value model. Companies that embrace this vision—and partner with technology providers like Q2BSTUDIO to build the underlying platforms—will be better positioned to accelerate discoveries, optimize resources, and generate real value. The study is dry-lab, but its implications for designing intelligent organizations are profound. The biotechnology of the future will not be organized as a set of departments, but as a central nervous system where every piece of data matters and every agent contributes to the same value map.
